pSivida Corp. (NASDAQ:PSDV) – Equities researchers at B. Riley upped their Q3 2018 EPS estimates for shares of pSivida in a research note issued on Thursday. B. Riley analyst A. D’silva now forecasts that the company will post earnings of ($0.14) per share for the quarter, up from their previous forecast of ($0.15). B. Riley has a “Buy” rating and a $5.00 price objective on the stock. B. Riley also issued estimates for pSivida’s Q4 2018 earnings at ($0.12) EPS and FY2018 earnings at ($0.54) EPS.

pSivida (NASDAQ:PSDV) last announced its quarterly earnings data on Wednesday, February 7th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.02. pSivida had a negative return on equity of 198.23% and a negative net margin of 882.37%. The company had revenue of $0.93 million for the quarter, compared to the consensus estimate of $0.48 million.

PSDV has been the topic of a number of other reports. HC Wainwright set a $5.00 price target on pSivida and gave the stock a “buy” rating in a research note on Thursday. ValuEngine downgraded pSivida from a “sell” rating to a “strong sell” rating in a research note on Friday, December 1st. Northland Securities reaffirmed a “buy” rating and set a $10.00 price target on shares of pSivida in a research note on Monday, December 11th. Finally, Laidlaw started coverage on pSivida in a research note on Wednesday, November 8th. They set a “buy” rating and a $5.00 price target on the stock. One research analyst has rated the stock with a sell rating and seven have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $7.57.

pSivida (PSDV) opened at $1.04 on Monday. pSivida has a 52 week low of $0.93 and a 52 week high of $2.45. The firm has a market capitalization of $47.07, a P/E ratio of -1.76 and a beta of 1.26.

A hedge fund recently bought a new stake in pSivida stock. OxFORD Asset Management LLP acquired a new position in pSivida Corp. (NASDAQ:PSDV) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 69,004 shares of the company’s stock, valued at approximately $118,000. OxFORD Asset Management LLP owned about 0.18% of pSivida as of its most recent SEC filing. Institutional investors and hedge funds own 9.70% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was originally published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this article on another publication, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this article can be accessed at

About pSivida

pSivida Corp. develops drug delivery products primarily for the treatment of chronic eye diseases. The Company operates through the biotechnology sector segment. The Company has developed three products for treatment of back-of-the-eye diseases, which include Medidur for posterior segment uveitis, its lead product candidate that is in pivotal Phase III clinical trials; ILUVIEN for diabetic macular edema (DME), its lead licensed product that is sold in the United States and European Union (EU) countries, and Retisert.

Receive News & Ratings for pSivida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for pSivida and related companies with's FREE daily email newsletter.